{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T03:23:38Z","timestamp":1790047418851,"version":"4.0.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), US Department of Health and Human Services","award":["HHSN272201500002C"],"award-info":[{"award-number":["HHSN272201500002C"]}]},{"name":"Vaccine and Treatment Evaluation Units","award":["HHSN272201300017I"],"award-info":[{"award-number":["HHSN272201300017I"]}]},{"name":"Vaccine and Treatment Evaluation Units","award":["HHSN2722013000201"],"award-info":[{"award-number":["HHSN2722013000201"]}]},{"name":"National Institute of Allergy and Infectious Diseases of the National Institutes of Health","award":["5T32AI100851"],"award-info":[{"award-number":["5T32AI100851"]}]},{"name":"National Institute on Aging, Duke Pepper Older Americans Independence Center","award":["NIA P30AG028716"],"award-info":[{"award-number":["NIA P30AG028716"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["1U24-MD016258"],"award-info":[{"award-number":["1U24-MD016258"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201500006I"],"award-info":[{"award-number":["HHSN272201500006I"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201300017I"],"award-info":[{"award-number":["HHSN272201300017I"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1K24-AI143971"],"award-info":[{"award-number":["1K24-AI143971"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["HHSN275201000003I"],"award-info":[{"award-number":["HHSN275201000003I"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["5U18-FD006298"],"award-info":[{"award-number":["5U18-FD006298"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s40262-022-01198-z","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T10:03:15Z","timestamp":1673517795000},"page":"127-139","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Population Pharmacokinetics of Piperacillin\/Tazobactam Across the Adult Lifespan"],"prefix":"10.1007","volume":"62","author":[{"given":"Marion","family":"Hemmersbach-Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Balevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia L.","family":"Winokur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia B.","family":"Landersdorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin W.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cohen-Wolkowiez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Conrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohua","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl M. J.","family":"Kirkpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geeta K.","family":"Swamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel B.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth E.","family":"Schmader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,12]]},"reference":[{"issue":"2","key":"1198_CR1","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.amjopharm.2004.12.005","volume":"2004","author":"BJ Cusack","year":"2004","unstructured":"Cusack BJ. Pharmacokinetics in older persons. Am J Geriatr Pharmacother. 2004;2004(2):274\u2013302.","journal-title":"Am J Geriatr Pharmacother"},{"key":"1198_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","volume":"57","author":"AA Mangoni","year":"2004","unstructured":"Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57:6\u201314.","journal-title":"Br J Clin Pharmacol"},{"key":"1198_CR3","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1053\/j.ajkd.2003.09.026","volume":"43","author":"AD Rule","year":"2004","unstructured":"Rule AD, Gussak HM, Pond GR, et al. Measured and estimated GFR in healthy potential kidney donors. Am J Kidney Dis. 2004;43:112\u20139.","journal-title":"Am J Kidney Dis"},{"key":"1198_CR4","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.idc.2017.07.011","volume":"31","author":"JM Benson","year":"2017","unstructured":"Benson JM. Antimicrobial pharmacokinetics and pharmacodynamics in older adults. Infect Dis Clin N Am. 2017;31:609\u201317.","journal-title":"Infect Dis Clin N Am"},{"key":"1198_CR5","unstructured":"United States Food and Drug Administration (FDA). Piperacillin\/tazobactam for injection, Wyeth Pharmaceuticals, Philadelphia, PA. 2015. Updated May 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/050684s88s89s90_050750s37s38s39lbl.pdf. Accessed 11 Jul 2022."},{"key":"1198_CR6","unstructured":"United States Food and Drug Administration (FDA). Zosyn\u00ae (piperacillin and tazobactam injection) in Galaxy\u00ae containers (PL 2040 plastic). Updated February 2007 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/050750s015lbl.pdf. Accessed 11 Jul 2022."},{"key":"1198_CR7","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1128\/AAC.00521-12","volume":"56","author":"TW Felton","year":"2012","unstructured":"Felton TW, Hope WW, Lomaestro BM, et al. Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections. Antimicrob Agents Chemother. 2012;56:4087\u201394.","journal-title":"Antimicrob Agents Chemother"},{"key":"1198_CR8","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1503\/cmaj.050051","volume":"173","author":"K Rockwood","year":"2005","unstructured":"Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173:489\u201395.","journal-title":"CMAJ"},{"key":"1198_CR9","doi-asserted-by":"publisher","first-page":"e02093","DOI":"10.1128\/AAC.02093-19","volume":"64","author":"SN Kalaria","year":"2020","unstructured":"Kalaria SN, Gopalakrishnan M, Heil EL. A population pharmacokinetics and pharmacodynamics approach to optimize tazobactam activity in critically ill patients. Antimicrob Agents Chemother. 2020;64:e02093-e2119.","journal-title":"Antimicrob Agents Chemother"},{"key":"1198_CR10","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/FTD.0b013e3182587665","volume":"34","author":"M Cohen-Wolkowiez","year":"2012","unstructured":"Cohen-Wolkowiez M, Benjamin DK Jr, Ross A, et al. Population pharmacokinetics of piperacillin using scavenged samples from preterm infants. Ther Drug Monit. 2012;34:312\u20139.","journal-title":"Ther Drug Monit"},{"key":"1198_CR11","doi-asserted-by":"publisher","first-page":"e01260","DOI":"10.1128\/AAC.01260-19","volume":"63","author":"C Thibault","year":"2019","unstructured":"Thibault C, Lavigne J, Litalien C, Kassir N, Th\u00e9or\u00eat Y, Autmizguine J. Population pharmacokinetics and safety of piperacillin\/tazobactam extended infusions in infants and children. Antimicrob Agents Chemother. 2019;63:e01260-e1319.","journal-title":"Antimicrob Agents Chemother"},{"key":"1198_CR12","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1128\/AAC.00102-15","volume":"59","author":"KM Watt","year":"2015","unstructured":"Watt KM, Gonzalez D, Benjamin DK Jr, et al. Fluconazole population pharmacokinetics and dosing for prevention and treatment of invasive Candidiasis in children supported with extracorporeal membrane oxygenation. Antimicrob Agents Chemother. 2015;59:3935\u201343.","journal-title":"Antimicrob Agents Chemother"},{"key":"1198_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3390\/antibiotics9030113","volume":"9","author":"N Ishihara","year":"2020","unstructured":"Ishihara N, Nishimura N, Ikawa K, et al. Population pharmacokinetic modeling and pharmacodynamic target attainment simulation of piperacillin\/tazobactam for dosing optimization in late elderly patients with pneumonia. Antibiotics (Basel). 2020;9:113.","journal-title":"Antibiotics (Basel)."},{"key":"1198_CR14","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1053\/j.semperi.2015.08.007","volume":"39","author":"K Zimmerman","year":"2015","unstructured":"Zimmerman K, Gonzalez D, Swamy GK, Cohen-Wolkowiez M. Pharmacologic studies in vulnerable populations: using the pediatric experience. Semin Perinatol. 2015;39:532\u20136.","journal-title":"Semin Perinatol"},{"key":"1198_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116769","volume":"10","author":"H Yang","year":"2015","unstructured":"Yang H, Zhang C, Zhou Q, Wang Y, Chen L. Clinical outcomes with alternative dosing strategies for piperacillin\/tazobactam: a systematic review and meta-analysis. PLoS ONE. 2015;10: e0116769.","journal-title":"PLoS ONE"},{"key":"1198_CR16","volume-title":"Hazzard\u2019s geriatric medicine and gerontology","author":"KP High","year":"2017","unstructured":"High KP, et al. Infection: general principles. Chapter 125. In: Halter JB, Ouslander JG, Studenski S, High KP, Asthana S, Supiano MA, et al., editors. Hazzard\u2019s geriatric medicine and gerontology. 7th ed. New York: McGraw-Hill Education; 2017.","edition":"7"},{"key":"1198_CR17","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S1473-3099(17)30615-1","volume":"18","author":"KZ Vardakas","year":"2018","unstructured":"Vardakas KZ, Voulgaris GL, Maliaros A, Samonis G, Falagas ME. Prolonged versus short-term intravenous infusion of antipseudomonal \u03b2-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials. Lancet Infect Dis. 2018;18:108\u201320.","journal-title":"Lancet Infect Dis"},{"key":"1198_CR18","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/CCM.0000000000002836","volume":"46","author":"NJ Rhodes","year":"2018","unstructured":"Rhodes NJ, Liu J, O\u2019Donnell JN, et al. Prolonged infusion piperacillin-tazobactam decreases mortality and improves outcomes in severely ill patients: results of a systematic review and meta-analysis. Crit Care Med. 2018;46:236\u201343.","journal-title":"Crit Care Med"},{"key":"1198_CR19","doi-asserted-by":"publisher","first-page":"e02571","DOI":"10.1128\/AAC.02571-19","volume":"64","author":"E Tannous","year":"2020","unstructured":"Tannous E, Lipman S, Tonna A, et al. Time above the MIC of piperacillin\/tazobactam as a predictor of outcome in Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother. 2020;64:e02571-e2619.","journal-title":"Antimicrob Agents Chemother"},{"key":"1198_CR20","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1097\/01.CCM.0000217961.75225.E9","volume":"34","author":"A Kumar","year":"2006","unstructured":"Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589\u201396.","journal-title":"Crit Care Med"},{"key":"1198_CR21","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1159\/000193996","volume":"55","author":"WG Bellman-Weiler","year":"2009","unstructured":"Bellman-Weiler WG. Pitfalls in the diagnosis and therapy of infections in elderly patients: a mini-review. Gerontology. 2009;55:241\u20139.","journal-title":"Gerontology"},{"key":"1198_CR22","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s10156-013-0605-x","volume":"19","author":"F Karino","year":"2013","unstructured":"Karino F, Miura K, Fuchita H, et al. Efficacy and safety of piperacillin\/tazobactam versus biapenem in late elderly patients with nursing- and healthcare-associated pneumonia. J Infect Chemother. 2013;19:909\u201315.","journal-title":"J Infect Chemother"},{"key":"1198_CR23","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.1532-5415.1985.tb07117.x","volume":"33","author":"RD Lindeman","year":"1985","unstructured":"Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 1985;33:278\u201385.","journal-title":"J Am Geriatr Soc"},{"key":"1198_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129036","volume":"10","author":"M Baba","year":"2015","unstructured":"Baba M, Shimbo T, Horio M, et al. Longitudinal study of the decline in renal function in healthy subjects. PLoS ONE. 2015;10: e0129036.","journal-title":"PLoS ONE"},{"key":"1198_CR25","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/01.mjt.0000183719.84390.4d","volume":"14","author":"ES ElDesoky","year":"2007","unstructured":"ElDesoky ES. Pharmacokinetic-pharmacodynamic crisis in the elderly. Am J Ther. 2007;14:488\u201398.","journal-title":"Am J Ther"},{"key":"1198_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1586\/ecp.12.75","volume":"6","author":"AA Mangoni","year":"2013","unstructured":"Mangoni AA, Jansen PA, Jackson SH. Under-representation of older adults in pharmacokinetic and pharmacodynamic studies: a solvable problem? Expert Rev Clin Pharmacol. 2013;6:35\u20139.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1198_CR27","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/cid\/ciu402","volume":"59","author":"NJ Rhodes","year":"2014","unstructured":"Rhodes NJ, MacVane SH, Kuti JL, Scheetz MH. Impact of loading doses on the time to adequate predicted beta-lactam concentrations in prolonged and continuous infusion dosing schemes. Clin Infect Dis. 2014;59:905\u20137.","journal-title":"Clin Infect Dis"},{"key":"1198_CR28","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/A:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28:481\u2013504.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1198_CR29","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/psp4.12319","volume":"7","author":"KM Jamsen","year":"2018","unstructured":"Jamsen KM, Patel K, Nieforth K, Kirkpatrick CMJ. A regression approach to visual predictive checks for population pharmacometric models. CPT Pharmacometrics Syst Pharmacol. 2018;7:678\u201386.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1198_CR30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1086\/510079","volume":"44","author":"PG Ambrose","year":"2007","unstructured":"Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it\u2019s not just for mice anymore. Clin Infect Dis. 2007;44:79\u201386.","journal-title":"Clin Infect Dis"},{"key":"1198_CR31","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/jac\/dki079","volume":"55","author":"JW Mouten","year":"2005","unstructured":"Mouten JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic\/pharmacodynamic (PK\/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother. 2005;55:601\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"1198_CR32","doi-asserted-by":"publisher","first-page":"5715","DOI":"10.1128\/AAC.00937-12","volume":"56","author":"CB Landersdorfer","year":"2012","unstructured":"Landersdorfer CB, Bulitta JB, Kirkpatrick CMJ, et al. Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile. Antimicrob Agents Chemother. 2012;56:5715\u201323.","journal-title":"Antimicrob Agents Chemother"},{"key":"1198_CR33","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1093\/jac\/dkp139","volume":"64","author":"JA Roberts","year":"2009","unstructured":"Roberts JA, Kirkpatrick CMJ, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother. 2009;64:142\u201350.","journal-title":"J Antimicrob Chemother"},{"key":"1198_CR34","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1128\/AAC.49.5.1881-1889.2005","volume":"49","author":"WA Krueger","year":"2005","unstructured":"Krueger WA, Bulitta J, Kinzig-Schippers M, et al. Evaluation by Monte Carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob Agents Chemother. 2005;49:1881\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"26","key":"1198_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/516284","volume":"1998","author":"WA Craig","year":"1998","unstructured":"Craig WA. Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;1998(26):1\u201310 (quiz 11\u20132).","journal-title":"Clin Infect Dis"},{"key":"1198_CR36","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/nrmicro862","volume":"2","author":"GL Drusano","year":"2004","unstructured":"Drusano GL. Antimicrobial pharmacodynamics: critical interactions of \u2018bug and drug.\u2019 Nat Rev Microbiol. 2004;2:289\u2013300.","journal-title":"Nat Rev Microbiol"},{"key":"1198_CR37","doi-asserted-by":"publisher","first-page":"e02306","DOI":"10.1128\/AAC.02306-17","volume":"62","author":"MG Andersen","year":"2018","unstructured":"Andersen MG, Thorsted A, Storgaard M, Kristoffersson AN, Friberg LE, \u00d6brink-Hansen K. Population pharmacokinetics of piperacillin in sepsis patients: should alternative dosing strategies be considered? Antimicrob Agents Chemother. 2018;62:e02306-e2317.","journal-title":"Antimicrob Agents Chemother"},{"key":"1198_CR38","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ijantimicag.2019.06.016","volume":"54","author":"L Ehmann","year":"2019","unstructured":"Ehmann L, Zoller M, Minichmayr IK, et al. Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic\/pharmacodynamic analysis. Int J Antimicrob Agents. 2019;54:309\u201317.","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl. 2","key":"1198_CR39","doi-asserted-by":"publisher","first-page":"S266","DOI":"10.1093\/clinids\/24.Supplement_2.S266","volume":"24","author":"WA Craig","year":"1997","unstructured":"Craig WA. The pharmacology of meropenem, a new carbapenem antibiotic. Clin Infect Dis. 1997;24(Suppl. 2):S266\u201375.","journal-title":"Clin Infect Dis"},{"key":"1198_CR40","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1093\/jac\/dkw153","volume":"71","author":"PJ Bergen","year":"2016","unstructured":"Bergen PJ, Bulitta JB, Kirkpatrick CMJ, et al. Effect of different renal function on antibacterial effects of piperacillin against Pseudomonas aeruginosa evaluated via the hollow-fibre infection model and mechanism-based modelling. J Antimicrob Chemother. 2016;71:2509\u201320.","journal-title":"J Antimicrob Chemother"},{"key":"1198_CR41","doi-asserted-by":"publisher","first-page":"e02642","DOI":"10.1128\/AAC.02642-16","volume":"61","author":"PJ Bergen","year":"2017","unstructured":"Bergen PJ, Bulitta JB, Kirkpatrick CMJ, et al. Substantial impact of altered pharmacokinetics in critically ill patients on the antibacterial effects of meropenem evaluated via the dynamic hollow-fiber infection model. Antimicrob Agents Chemother. 2017;61:e02642-e2716.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. A","key":"1198_CR42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/jac\/31.suppl_A.39","volume":"31","author":"F S\u00f6rgel","year":"1993","unstructured":"S\u00f6rgel F, Kinzig M. The chemistry, pharmacokinetics and tissue distribution of piperacillin\/tazobactam. J Antimicrob Chemother. 1993;31(Suppl. A):39\u201360.","journal-title":"J Antimicrob Chemother"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01198-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-022-01198-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-022-01198-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T16:44:37Z","timestamp":1675442677000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-022-01198-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["1198"],"URL":"https:\/\/doi.org\/10.1007\/s40262-022-01198-z","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"11 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services, through Contract No. HHSN272201500002C (Emmes), and a Vaccine and Treatment Evaluation Units award under Contract No. HHSN272201300017I (Duke University) and Contract No. HHSN2722013000201 (University of Iowa). This work was also supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (grant number 5T32AI100851 to MHM). KES also received support from the National Institute on Aging, Duke Pepper Older Americans Independence Center, NIA P30AG028716. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. MCW receives support for research from the NIH [1U24-MD016258], National Institute of Allergy and Infectious Diseases [HHSN272201500006I, HHSN272201300017I, 1K24-AI143971], NICHD [HHSN275201000003I], US Food and Drug Administration [5U18-FD006298], and industry for drug development in adults and children.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"SJB receives support from the National Institutes of Health, the US Food and Drug Administration, the Patient-Centered Outcomes Research Institute, the Rheumatology Research Foundation\u2019s Scientist Development Award, the Childhood Arthritis and Rheumatology Research Alliance, Purdue Pharma, and consulting for UCB. The remaining authors have no relevant disclosures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was reviewed and approved by the institutional review board at the respective study sites.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained by patients or their legally authorized representative.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Patients signed informed consent regarding the publishing of their data.\u00a0 They were informed their identity will not be revealed.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Data are to be made available as widely as possible, while safeguarding the privacy of participants, and protecting confidential and proprietary data.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"MH-M: conception and design of the analysis, acquisition, interpretation of data for the work, and revising the work critically for important intellectual content. SJB: conception and design of the analysis, acquisition, interpretation of data for the work, and revising the work critically for important intellectual content. PLW: conception and design of the analysis, acquisition, interpretation of data for the work, and revising the work critically for important intellectual content. CBL: conception and design of the analysis, acquisition, interpretation of data for the work, and revising the work critically for important intellectual content. KG: conception and design of the analysis, acquisition, interpretation of data for the work, and revising the work critically for important intellectual content. AWC: conception and design of the analysis, acquisition, interpretation of data for the work, and revising the work critically for important intellectual content. MC-W: conception and design of the analysis, acquisition, interpretation of data for the work, and revising the work critically for important intellectual content. TC: conception and design of the analysis, acquisition, interpretation of data for the work, and revising the work critically for important intellectual content. GA: conception and design of the analysis, acquisition, interpretation of data for the work, and revising the work critically for important intellectual content. CMJK: conception and design of the analysis, acquisition, interpretation of data for the work, and revising the work critically for important intellectual content. GKS: conception and design of the analysis, acquisition, interpretation of data for the work, and revising the work critically for important intellectual content. EBW: conception and design of the analysis, acquisition, interpretation of data for the work, and revising the work critically for important intellectual content. KES: conception and design of the analysis, acquisition, interpretation of data for the work, and revising the work critically for important intellectual content.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}